Fobrepodacin Biochemical

Fobrepodacin

CATALOG #
AAA227638


PRODUCT SYNONYMS

Fobrepodacin; Fobrepodacin biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	1384984-31-9
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	Fobrepodacin (oral gavage; 10, 30, 100 mg/kg; once per day; 5 times per week for 4 weeks) reduces the mycobacterial burden in a model of chronic tuberculosis infection in mice[1]. Fobrepodacin (oral; 100 mg/kg; once per day; 5 days per week, for 8 weeks) improves the bactericidal activities of antimycobacterial drugs[1]. Animal Model: Six-week old female BALB/c and C57BL/6 mice uninfected or M. tuberculosis-infected (Erdman)[1]. Dosage: 10, 30, 100 mg/kg. Administration: Oral gavage; once per day; 5 times per week for 4 weeks. Result: Reduced the mycobacterial burden in a model of chronic tuberculosis infection in mice.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
BNM-III-170, CAS 1859189-55-1



Structure
BNM-III-170, CAS 1859189-55-1

ADDITIONAL INFORMATION

Related Product Information for Fobrepodacin biochemical	Fobrepodacin (SPR720) is an orally active and potent phosphate prodrug of SPR719 (VXc-486; HY-12930). Fobrepodacin has potent bactericidal activities in vivo.
References	1. Fritschi CJ, et al. Identification of gp120 Residue His105 as a Novel Target for HIV-1 Neutralization by Small-Molecule CD4-Mimics. ACS Med Chem Lett. 2021 Oct 29;12(11):1824-1831.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.